Literature DB >> 5041775

11-hydroxy- 9 -tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man.

L Lemberger, R E Crabtree, H M Rowe.   

Abstract

11-Hydroxy-Delta(9)-tetrahydrocannabinol, administered intravenously to man, produces psychologic and pharmacologic effects that persist for several hours. The drug and its metabolites are excreted in urine and feces for more than 1 week. The pharmacology, disposition, and metabolism of 11-hydroxy-Delta(9)-tetra-hydrocannabinol mimic that of Delta(9)-tetrahydrocannabinol, thus providing evidence that Delta(9)-tetrahydrocannabinol (the major active component of marihuana) is converted to the 11-hydroxy compound in man, the latter compound being responsible for the effects.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5041775     DOI: 10.1126/science.177.4043.62

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  20 in total

Review 1.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

2.  Differential signalling in human cannabinoid CB1 receptors and their splice variants in autaptic hippocampal neurones.

Authors:  Alex Straiker; Jim Wager-Miller; Jacqueline Hutchens; Ken Mackie
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  Δ9-Tetrahydrocannabinol changes the brain lipidome and transcriptome differentially in the adolescent and the adult.

Authors:  Emma Leishman; Michelle Murphy; Ken Mackie; Heather B Bradshaw
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-02-08       Impact factor: 4.698

4.  Human Pharmacokinetic Parameters of Orally Administered Δ9-Tetrahydrocannabinol Capsules Are Altered by Fed Versus Fasted Conditions and Sex Differences.

Authors:  Stephanie Lunn; Patrick Diaz; Shannon O'Hearn; Shaina P Cahill; Alexia Blake; Kelly Narine; Jason R B Dyck
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-06

5.  Cannabidiol and cannabinol in man.

Authors:  L E Hollister
Journal:  Experientia       Date:  1973

6.  Quantifying Hepatic Enzyme Kinetics of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling.

Authors:  Gabriela I Patilea-Vrana; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2019-05-02       Impact factor: 3.922

7.  Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.

Authors:  Linda E Klumpers; Tim L Beumer; Johan G C van Hasselt; Astrid Lipplaa; Lennard B Karger; H Daniël Kleinloog; Jan I Freijer; Marieke L de Kam; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

Review 8.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.

Authors:  Eugene W Schwilke; David M Schwope; Erin L Karschner; Ross H Lowe; William D Darwin; Deanna L Kelly; Robert S Goodwin; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-10-15       Impact factor: 8.327

10.  Gonadal hormone modulation of ∆9-tetrahydrocannabinol-induced antinociception and metabolism in female versus male rats.

Authors:  R M Craft; A E Haas; J L Wiley; Z Yu; B H Clowers
Journal:  Pharmacol Biochem Behav       Date:  2016-09-24       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.